StreetAlpha.app
Home › Stocks › ANAB

Anaptysbio, Inc (ANAB)

Healthcare
$45.61
▼ −0.26%
LAST CLOSE · NOV 17

AnaptysBio collects royalties from the cancer treatment Jemperli and the psoriasis treatment Quimilza, which partners GSK and Vanda sell. It last closed at $45.61 on Nov 17, down 0.26% on the day. ANAB last reported earnings on Wed, Sep 23, 2026. The average 12-month price target from 3 analysts is $70.33 (+54.2% from the last close), with a high of $81.00 and a low of $60.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in ANAB, 100% of them bullish and 0% bearish.

AI Auto Pilots
Is ANAB in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$191.6M
+13.0% vs a year ago
Net income
$184.5M
96.3% margin
EPS (diluted)
$5.33
Operating margin
155.6%
$298.1M operating income
Valuation
Market cap
$1.4B
29.7M shares
P/E
8.6
Price over 12 month EPS
Price to sales
7.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$135.4M
At Sep 30
Shareholder equity
$20.8M
Buybacks
$3.4M
Last 12 months
Fiscal year endsJune
ExchangeNasdaq
Financials history
FY2021: $63.2M$63.2MFY2021FY2022: $10.3M$10.3MFY2022FY2023: $17.2M$17.2MFY2023FY2024: $91.3M$91.3MFY2024FY2025: $234.6M$234.6MFY2025

From ANAB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Sep 23
2026 · Time not announced
Reported EPS
-$1.34
vs -$0.22 est. · miss
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on ANAB in the past 90 days
Average 12-month target
$70.33
▲ 54.2% upside

Based on 3 analysts who set a price target on ANAB in the past 90 days. The average target is $70.33, with a high of $81.00 and a low of $60.00, compared with the last close of $45.61.

Low $60.00Avg $70.33High $81.00
Blue marker: last close $45.61
Highest target$81.00
Average target$70.33
Lowest target$60.00
Latest rating changes
JP MorganMaintained
Sep 30Buy$60
Leerink PartnersMaintained
Sep 23Buy$81
TD CowenMaintained
Aug 25Buy$70
HC Wainwright & Co.Assumed coverage
Jun 10Buy$95
DateFirmActionRatingPrice target
Sep 30JP MorganMaintainedBuy$60
Sep 23Leerink PartnersMaintainedBuy$81
Aug 25TD CowenMaintainedBuy$70
Jun 10HC Wainwright & Co.Assumed coverageBuy$95
Loading…

Technical Analysis

ANAB · as of the Nov 17 close · updated after every close
Turning down

The stock is 5% below its 20 day and 8% below its 50 day average. It is 13% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 41). The nearest support is the Pivot at $45.59, and the nearest resistance the Pivot R1 at $46.19.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNormal
VolatilityLow, 4.4%/day
Key levels
$72.3652 week high+58.6%
$53.70100 day average+17.7%
$51.33200 day average+12.5%
$49.3550 day average+8.2%
$49.00Swing high (Nov 4)+7.4%
$47.7620 day average+4.7%
$46.19Pivot R1+1.3%
$45.61Last close
$45.59Pivot−0.0%
$45.45Swing low (Nov 6)−0.4%
$45.01Pivot S1−1.3%
$22.0152 week low−51.7%
Indicators
RSI (14)40.80Middle of its rangeNeutral
MACD-0.78Below its signal lineBearish
Stochastic18.6Near the bottom of its rangeOversold
ADX (14)23.5Weak trend
Williams %R-85.3Oversold below −80, overbought above −20Oversold
CCI (20)-143.7Oversold below −100, overbought above 100Oversold
Rate of change−4.4%Change over 10 sessionsBearish
ATR (14)$2.00Typical daily range, 4.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ANAB

What happened before

See how ANAB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ANAB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ANAB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Oct 5 – Oct 5
Loading…

See today’s whale options flow across the market →

ANAB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲137 buying vs 98 selling
  • ▲Held by funds +2.3 pts
  • ▲Funds holding +15
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding229214+7.0%
In funds' top 1067−14.3%
Held by funds103.7%101.4%+2.3 pts
New / increased50 / 8744 / 75+15.1%
Reduced / sold out63 / 3564 / 37−3.0%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ANAB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANAB is in one of them and how their past ANAB trades turned out.

ANAB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ANAB in an article yet. Here's the latest on the wider market.

About Anaptysbio

AnaptysBio is a pharmaceutical company based in San Diego, California, whose business centers on collecting royalties from medicines it has licensed to others. It receives royalties on Jemperli, a cancer treatment developed and sold by GSK, and on Quimilza, a treatment for generalized pustular psoriasis that Vanda Pharmaceuticals is developing and commercializing. The company does not develop or sell these products itself, so its payments depend on the sales of its partners.

Headquarters
San Diego, CA